← Eichor
Study identifier: NCT06050668 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Essential Amino Acid Supplementation for Femoral Fragility Fractures

Condition: Femoral Fracture · Fragility Fracture · Muscle Atrophy  ·  Sponsor: Michael C Willey

PhasePhase 2
Planned participants60
Who can joinAll sexes, 65 Years to no upper limit
Healthy volunteersNo

About this study

This trial will evaluate the impact of 4 weeks of postoperative essential amino acid (EAA)-based supplementation on muscle morphology after femoral fragility fracture. This trial will assess the ability of EAA-based to increase skeletal muscle metabolic activity, reduce inflammation, and induce muscle fiber hypertrophy, as well as preserve skeletal muscle mass and physical performance up to 6 months after injury. Participants will be randomized in a 1:1 ratio to 1) standard of care (no dietary intervention) or 2) EAA-based supplementation.

This description comes directly from the study's public registry record.

Talk to the study team

Michael C Willey, MD  ·  319-384-8452  ·  michael-willey@uiowa.edu

Ashley S Kochuyt, BS  ·  319-929-3559  ·  ashley-kochuyt@uiowa.edu

Always discuss trial participation with your own doctor first.

Locations (2)

University of Iowa Health CareIowa City, Iowa, United StatesRecruiting
Slocum Center for Orthopedics & Sports MedicineEugene, Oregon, United StatesNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06050668